# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248

> **NCT04036227** · PHASE1 · COMPLETED · sponsor: **Gesynta Pharma AB** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GS-248
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04036227
- **Lead sponsor:** Gesynta Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-03
- **Primary completion:** 2019-12-20
- **Final completion:** 2019-12-20
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2023-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04036227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04036227, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04036227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*